Free provider profile
JOHN NIENOW, MD
Need more providers like JOHN NIENOW?
See the count and top 3 free, ranked by Medicare billing. Full list $29, included with membership.
Rep intel
What JOHN NIENOW prescribes and who else does
Top Medicare Part D drugs by claims (public CMS data):
- Biktarvy
- Descovy
- Tivicay
- Juluca
- Triumeq
See all internal medicine physicians in CA who bill Medicare →
Your next referral list starts here
Provider + market indicator
A combined screening indicator—not a provider fraud-risk score. Local plan ratings describe the surrounding market, not this provider’s quality, plan membership or wrongdoing.
Comparing current CMS billing with peers and checking OIG and plan ratings… A new peer comparison can take about a minute.
Practice contact card
Practice phone
415-202-1550
Fax
415-776-8233
Practice address
2186 GEARY BLVD STE 314, SAN FRANCISCO, CA, 94115
- Registry updated
- 2025-05-06
- NPI issued
- 2006-01-18
- RepVector retrieved
- 11/21/2026
A recent retrieval can still contain an old address if the provider has not updated their registry record. Website email checks show their own date under Find email.
Registry record
Source: CMS NPPES registry.
2186 GEARY BLVD STE 314, SAN FRANCISCO, CA, 94115
415-202-1550
2 practice locations listed
Enumerated 2006-01-18
- — Registration is active in NPPES.
- — Individual clinician record — reachable, but usually not the buyer.
- — Practice phone number is published.
- — Full street address on file for route planning.
- — 2 practice locations listed — multi-site footprint.
- — Record updated within the last three years.
Medicare Part D prescribing
Source: CMS Medicare Part D Prescribers by Provider, most recent public year.
Part D claims
10,815
Medicare patients
392
Part D drug cost
$8,267,532
Brand-name share
26.4%
of this prescriber's Part D claims
| Drug | Claims | Medicare cost |
|---|---|---|
| Biktarvy (Bictegrav/Emtricit/Tenofov Ala) | 680 | $3,026,909 |
| Tivicay (Dolutegravir Sodium) | 215 | $629,176 |
| Descovy (Emtricitabine/Tenofov Alafenam) | 224 | $558,227 |
| Serostim (Somatropin) | 29 | $545,676 |
| Juluca (Dolutegravir/Rilpivirine) | 121 | $485,317 |
| Triumeq (Abacavir/Dolutegravir/Lamivudi) | 98 | $426,609 |
| Egrifta Sv (Tesamorelin Acetate) | 34 | $307,433 |
| Rukobia (Fostemsavir Tromethamine) | 21 | $192,880 |
Want their full drug mix and peer benchmark? Run the free Part D prescriber lookup.
Latest Medicare Part B billing
CMS Physician and Other Practitioners, by Provider and Service. New published billing years are detected daily, using the same release as the Billing analyst and risk maps.
Loading the latest published CMS billing file…
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
Checking Open Payments…
Industry payments across CA — which companies pay providers there.
Open Payments page for this provider
- Registry data comes straight from CMS NPPES, which lists registration, not activity — a listed practice may have moved or closed.
- Part D covers Medicare prescription drug enrollees only. Commercial, Medicaid and cash-pay prescribing is not included, so these figures are a floor on real volume, not the whole picture.
- CMS publishes the Part D file annually, roughly two years behind the prescribing year. Drugs with 10 or fewer claims are suppressed.
